AXT adds new range of microscopes suited to in situ incubator applications

AXT adds new range of microscopes suited to in situ incubator applications

AXT enhances cellular research product portfolio with solutions from StemBioSys The Lumascope range of microscopes is designed specifically for the examination and analysis of live cell morphology, viability and growth. Etaluma has designed the Lumascope from the ground up. By starting with the application, they are able to avoid redundant features seen in traditional inverted microscopes and instead focus on a custom design for a specific need. Etaluma’s range of microscopes represents a new concept in digital fluorescence microscopy, which forms the backbone of life science imaging. Capable of produce high-quality multichannel images of both fixed and live samples, they feature zero pixel shift filters, high-resolution camera sensors and modern LED light sources. With manual or automated options, they accommodate microplates, flasks, dishes, custom labware as well as slides which can be examined in situ inside incubators, biological safety cabinets and other environmentally controlled workstations. Chris Shumate, CEO of Etaluma said: We are excited to be working with the AXT team who have an excellent reputation and footprint in the life science microscopy market. We have every confidence that they will grow our market share in Australia and New Zealand." Etaluma's range of microscopes will make an excellent addition to our product range and support our strategy to bring technologies that enable better live cell imaging to market. Their products are unrivalled on a cost to performance basis. We look forward to showing the capabilities of the Lumascopes to our customers." Richard Trett, AXT’s Managing Director Etaluma’s range of live cell imaging microscopes will complement AXT’s existing range of cell biology solutions. Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More